-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Synaptogenix (NASDAQ:SNPX) Stock Price Down 3.7%
Synaptogenix (NASDAQ:SNPX) Stock Price Down 3.7%
Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating)'s share price was down 3.7% during trading on Tuesday . The stock traded as low as $7.85 and last traded at $7.99. Approximately 30,751 shares traded hands during trading, a decline of 67% from the average daily volume of 92,223 shares. The stock had previously closed at $8.30.
Synaptogenix Stock Down 3.7 %
The business has a 50-day simple moving average of $6.41 and a two-hundred day simple moving average of $6.34. The stock has a market capitalization of $54.66 million, a price-to-earnings ratio of -3.80 and a beta of 0.91.
Get Synaptogenix alerts:Synaptogenix (NASDAQ:SNPX – Get Rating) last issued its quarterly earnings results on Friday, August 5th. The company reported ($0.54) EPS for the quarter.
Institutional Trading of Synaptogenix
Several hedge funds have recently added to or reduced their stakes in SNPX. Prelude Capital Management LLC lifted its stake in Synaptogenix by 13.9% during the second quarter. Prelude Capital Management LLC now owns 14,364 shares of the company's stock worth $75,000 after purchasing an additional 1,750 shares during the period. Renaissance Technologies LLC bought a new position in shares of Synaptogenix during the 2nd quarter worth approximately $83,000. Finally, Vanguard Group Inc. grew its position in Synaptogenix by 248.9% in the first quarter. Vanguard Group Inc. now owns 216,836 shares of the company's stock valued at $1,678,000 after acquiring an additional 154,688 shares during the period. Institutional investors own 9.10% of the company's stock.About Synaptogenix
(Get Rating)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Featured Articles
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Peak Inflation Sets the Bottom for Brinker International Stock
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Broadcom Bounces From Institutional Bottom
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating)'s share price was down 3.7% during trading on Tuesday . The stock traded as low as $7.85 and last traded at $7.99. Approximately 30,751 shares traded hands during trading, a decline of 67% from the average daily volume of 92,223 shares. The stock had previously closed at $8.30.
新創科技股份有限公司(納斯達克代碼:SNPX-GET Rating)股價週二下跌3.7%,最低報7.85美元,尾盤報7.99美元。全天約有30,751股股票易手,較平均日成交量92,223股下跌67%。該股此前收盤報8.30美元。
Synaptogenix Stock Down 3.7 %
Synaptogenix股價下跌3.7%
The business has a 50-day simple moving average of $6.41 and a two-hundred day simple moving average of $6.34. The stock has a market capitalization of $54.66 million, a price-to-earnings ratio of -3.80 and a beta of 0.91.
該業務的50日簡單移動均線切入位在6.41美元,200日簡單移動均線切入位在6.34美元。該股市值為5,466萬美元,市盈率為-3.8倍,貝塔係數為0.91。
Synaptogenix (NASDAQ:SNPX – Get Rating) last issued its quarterly earnings results on Friday, August 5th. The company reported ($0.54) EPS for the quarter.
Synaptogenix(納斯達克代碼:SNPX-GET Rating)上一次發佈季度收益報告是在8月5日星期五。該公司公佈了該季度每股收益(0.54美元)。
Institutional Trading of Synaptogenix
Synaptogenix的制度性交易
About Synaptogenix
關於Synaptogenix
(Get Rating)
(獲取評級)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Synaptogenix公司是一家生物製藥公司,在臨牀前和臨牀開發方面有候選產品。它專注於開發一個基於一種名為Bryostatin-1的候選藥物的產品平臺,用於治療阿爾茨海默病。該公司還在評估bryostatin在其他神經退行性或認知疾病和功能障礙方面的治療應用,如脆性X綜合徵、多發性硬化症和Niemann-Pick C型疾病。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Peak Inflation Sets the Bottom for Brinker International Stock
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Broadcom Bounces From Institutional Bottom
- 免費獲取StockNews.com關於Synaptogenix的研究報告(SNPX)
- 3低貝塔防禦性股票為艱難的市場做準備
- 對於這三隻股票來説,這可能是一個值得記住的9月
- 通脹峯值為布林克國際股票設定底部
- 在預訂增加的情況下,Roblox能否扭轉預訂量下降的局面
- 博通從機構底部反彈
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synaptogenix Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synaptogenix和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧